Copart vs Science Applications Intl
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Copart and Science Applications Intl side by side, using each one’s latest annual report. Here is what stands out:
- Science Applications Intl is the larger business, with $7.3B of revenue in fiscal 2026 against $4.7B for Copart, about 1.6 times as much.
- Copart grew revenue faster (0.4%, against −2.9%).
- Copart kept more of each dollar of sales as operating profit (35.4% operating margin, against 7.2%).
- Copart turned more of its sales into free cash flow (27.2% FCF margin, against 8.0%).
- Copart earned a higher return on the capital invested in it (19.6%, against 12.8%).
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Copart
CPRT
7/10
Revenue growth5-year growthOperating marginNet marginFCF marginReturn on capitalNet debt / EBITDA
Science Applications Intl
SAIC
3/10
Return on equityPiotroski F-scoreShare count change
Side by side
Best in the row
| Latest fiscal year | CPRT FY26 | SAIC FY26 |
|---|---|---|
| Size | ||
| Market cap | $27.9B | $6.4B |
| Revenue | $4.7B | $7.3B |
| Free cash flow | $1.3B | $577M |
| Net income | $1.5B | $358M |
| Growth | ||
| Revenue growth | 0.4% | −2.9% |
| 5-year growth | 11.6% | 0.6% |
| Share count change | −2.1% | −7.9% |
| Profitability | ||
| Gross margin | — | 12.0% |
| Operating margin | 35.4% | 7.2% |
| Net margin | 31.8% | 4.9% |
| FCF margin | 27.2% | 8.0% |
| Return on capital | 19.6% | 12.8% |
| Return on equity | 16.2% | 23.3% |
| Balance sheet | ||
| Net debt | −$1.9B | $2.3B |
| Net debt / EBITDA | −1.0x | 4.2x |
| Dividends and buybacks | $1.6B | $515M |
| Valuation & quality | ||
| P/E | — | 17.3x |
| Piotroski F-score | 4 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.